PolyPid Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains PolyPid(PYPD.US) With Buy Rating, Cuts Target Price to $11
PolyPid Analyst Ratings
JMP Securities Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $13
H.C. Wainwright Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $14
PolyPid Analyst Ratings
HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $14 Price Target
PolyPid's Strategic Advancements and Clinical Progress: A Buy Recommendation
Craig-Hallum Maintains PolyPid(PYPD.US) With Buy Rating
Barclays Maintains PolyPid(PYPD.US) With Hold Rating, Maintains Target Price $10
PolyPid (PYPD) Gets a Hold From Barclays
JMP Securities Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $13
Craig-Hallum Maintains PolyPid(PYPD.US) With Buy Rating
Craig-Hallum Maintains PolyPid(PYPD.US) With Buy Rating
Craig-Hallum Maintains PolyPid(PYPD.US) With Buy Rating
Craig-Hallum Maintains PolyPid(PYPD.US) With Buy Rating
Craig-Hallum Initiates PolyPid(PYPD.US) With Buy Rating, Announces Target Price $10
PolyPid Analyst Ratings
H.C. Wainwright Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $14
Buy Rating Affirmed for PolyPid on D-PLEX's Positive Trial Milestones and Commercial Prospects